Nestle Health Science, a company engaged in advancing the role for nutritional therapy, agreed to invest $200m in Aimmune Therapeutics, a biopharmaceutical company developing and commercializing treatment for potentially life-threatening food allergies. NHS's total investment to date in Aimmune Therapeutics is $473m, bringing its total equity ownership to 25.6%, of which just under 20% are regular voting shares. “We first invested in Aimmune in 2016 and have been closely involved since then. Their research and development approach is fully aligned with our mission of empowering healthier lives through science-based nutritional solutions. We expect Aimmune’s PALFORZIA™, the first medication approved by the United States Food and Drug Administration for food allergies in children and teens, to change the landscape of food allergy treatment and look forward to even more innovations,” Greg Behar, NHS's CEO and Aimmune Therapeutics Board Member.